479 related articles for article (PubMed ID: 20647327)
1. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
Kerkar SP; Muranski P; Kaiser A; Boni A; Sanchez-Perez L; Yu Z; Palmer DC; Reger RN; Borman ZA; Zhang L; Morgan RA; Gattinoni L; Rosenberg SA; Trinchieri G; Restifo NP
Cancer Res; 2010 Sep; 70(17):6725-34. PubMed ID: 20647327
[TBL] [Abstract][Full Text] [Related]
2. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
[TBL] [Abstract][Full Text] [Related]
3. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
[TBL] [Abstract][Full Text] [Related]
4. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8
Etxeberria I; Bolaños E; Quetglas JI; Gros A; Villanueva A; Palomero J; Sánchez-Paulete AR; Piulats JM; Matias-Guiu X; Olivera I; Ochoa MC; Labiano S; Garasa S; Rodriguez I; Vidal A; Mancheño U; Hervás-Stubbs S; Azpilikueta A; Otano I; Aznar MA; Sanmamed MF; Inogés S; Berraondo P; Teijeira Á; Melero I
Cancer Cell; 2019 Dec; 36(6):613-629.e7. PubMed ID: 31761658
[TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model.
Lisiero DN; Soto H; Liau LM; Prins RM
J Immunol; 2011 May; 186(9):5068-77. PubMed ID: 21430221
[TBL] [Abstract][Full Text] [Related]
6. Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.
Santos JM; Havunen R; Siurala M; Cervera-Carrascon V; Tähtinen S; Sorsa S; Anttila M; Karell P; Kanerva A; Hemminki A
Int J Cancer; 2017 Oct; 141(7):1458-1468. PubMed ID: 28614908
[TBL] [Abstract][Full Text] [Related]
7. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.
Quatromoni JG; Morris LF; Donahue TR; Wang Y; McBride W; Chatila T; Economou JS
J Hematol Oncol; 2011 Nov; 4():48. PubMed ID: 22112546
[TBL] [Abstract][Full Text] [Related]
8. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
9. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice.
Chinnasamy D; Yu Z; Kerkar SP; Zhang L; Morgan RA; Restifo NP; Rosenberg SA
Clin Cancer Res; 2012 Mar; 18(6):1672-83. PubMed ID: 22291136
[TBL] [Abstract][Full Text] [Related]
10. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
[TBL] [Abstract][Full Text] [Related]
12. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP
Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507
[TBL] [Abstract][Full Text] [Related]
13. Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity.
Komita H; Zhao X; Katakam AK; Kumar P; Kawabe M; Okada H; Braughler JM; Storkus WJ
Cancer Gene Ther; 2009 Dec; 16(12):883-91. PubMed ID: 19444303
[TBL] [Abstract][Full Text] [Related]
14. Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
Tucker CG; Mitchell JS; Martinov T; Burbach BJ; Beura LK; Wilson JC; Dwyer AJ; Singh LM; Mescher MF; Fife BT
J Immunol; 2020 Sep; 205(5):1449-1460. PubMed ID: 32737148
[TBL] [Abstract][Full Text] [Related]
15. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.
Kujawski M; Zhang C; Herrmann A; Reckamp K; Scuto A; Jensen M; Deng J; Forman S; Figlin R; Yu H
Cancer Res; 2010 Dec; 70(23):9599-610. PubMed ID: 21118964
[TBL] [Abstract][Full Text] [Related]
16. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
[TBL] [Abstract][Full Text] [Related]
18. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
19. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.
Zhang L; Kerkar SP; Yu Z; Zheng Z; Yang S; Restifo NP; Rosenberg SA; Morgan RA
Mol Ther; 2011 Apr; 19(4):751-9. PubMed ID: 21285960
[TBL] [Abstract][Full Text] [Related]
20. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
Antony PA; Piccirillo CA; Akpinarli A; Finkelstein SE; Speiss PJ; Surman DR; Palmer DC; Chan CC; Klebanoff CA; Overwijk WW; Rosenberg SA; Restifo NP
J Immunol; 2005 Mar; 174(5):2591-601. PubMed ID: 15728465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
